<DOC>
	<DOCNO>NCT01405508</DOCNO>
	<brief_summary>This multicenter , open-label , 4-arm , randomize , parallel-group study evaluate safety tolerability Brivaracetam Intravenous ( BRV iv ) adjunctive treatment adult epilepsy accord initiation conversion scheme , repeat dosing ( 100 mg/administration twice daily 4.5 day ) .</brief_summary>
	<brief_title>Safety Tolerability Intravenous Brivaracetam ( Infusion Bolus ) Adjunctive Antiepileptic Therapy</brief_title>
	<detailed_description>Eligible subject randomize 1:1:1:1 ratio 4 treatment arm</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>An Institutional Review Board/Independent Ethics Committee ( IRB/IEC ) approve write Informed Consent form sign date subject parent ( ) legal representative Subjects 16 70 year Subjects body weight &gt; /= 40 kg Female subject without childbearing potential female subject childbearing potential use medically accept contraceptive method Subject/legal representative consider reliable capable adhere protocol Subjects wellcharacterized focal generalized epilepsy epileptic syndrome Subjects history partialonset seizures whether secondarily generalize primary generalized seizure Subjects uncontrolled treat 1 2 permit concomitant antiepileptic drug ( AEDs ) Permitted concomitant antiepileptic drug ( AEDs ) vagus nerve stimulation ( VNS ) stable optimal dosage subject least 1 month Visit 1 expect keep stable RunIn Evaluation Periods Mentally impaired subject unable understand study purpose History presence status epilepticus 1 year precede Visit 1 Baseline Subjects felbamate le 18 month continuous exposure Visit 1 Subjects currently vigabatrin Subject take drug possible relevant central nervous system effect except stable least 1 month Visit 1 expect keep stable trial Subjects take drug may significantly influence metabolism Brivaracetam ( BRV ) except dose kept stable least 1 month Visit 1 , expect keep stable trial History cerebrovascular accident last 6 month Subjects suffer severe cardiovascular disease peripheral vascular disease Presence sign suggest rapidly progress brain disorder brain tumor Any clinical condition impair reliable participation study necessitate use medication allow protocol Presence terminal illness Presence serious infection Subjects history sever adverse hematologic reaction drug Subjects suffering severe disturbance hemostasis Impaired hepatic function : alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , gammaglutamyltransferase ( GGT ) value 3 time upper limit reference range Subjects clinically significant deviation reference range value laboratory parameter : creatinine clearance calculate &lt; 50 ml / min , platelet &lt; 100,000 / µL , neutrophil cell &lt; 1,800 / µL Clinically significant electrocardiogram ( ECG ) abnormalities accord Investigator History suicide attempt In Investigator 's medical judgment , current suicidal ideation serious psychiatric disorder require require hospitalization medication Known allergic reaction intolerance pyrrolidone derivative / investigational product excipients Known multiple drug allergy severe drug allergy Pregnant lactate woman Known alcohol drug addiction abuse within last 2 year Subject institutionalized judicial decision Problems venous accessibility Subject take part another clinical / pharmacological study month precede enrollment ( Visit 1 ) Investigators , coinvestigators , spouse child , study collaborator Subjects previously treat Brivaracetam ( BRV ) Subject previously screen within study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>N01258</keyword>
	<keyword>Brivaracetam</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>IV</keyword>
	<keyword>intravenous</keyword>
</DOC>